| Phase 1 | 2 | |
| Phase 1/2 | 1 | |
| Phase 2 | 2 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With… | Advanced Gastrointestinal Stromal Tumors | Recruiting | 2026-06-16 |
| Phase 2 | ||||
| NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Advanced Systemic Mastocytosis (AdvSM) | Recruiting | 2026-09-15 |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in… | SSM | Active, Not Recruiting | 2026-05-22 |
| Phase 1/2 | ||||
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other… | Intrahepatic Cholangiocarcinoma (Icc) | Active, Not Recruiting | 2026-04-17 |
| Phase 1 | ||||
| NCT07361562 | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Advanced Solid Tumor, Adult | Recruiting | 2026-09-04 |
| NCT07383506 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | PIK3CA Mutations | Recruiting | 2026-08-26 |
Breast Cancer (2) · Acute Myeloid Leukemia (AML) (1) · Cholangiocarcinoma (1) · Endometrial Cancer (1) · Leukemia (1) · Lung Cancer (1) · MDS/MPN Overlap (1) · Non-Small Cell Lung Cancer (NSCLC) (1)